Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Arsenic Trioxide

            Therapeutic Area: Immunology Product Name: Arscimed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Phebra

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 30, 2021

            Details:

            Exclusive licensing agreement for the development of a patented formulation of oral arsenic trioxide in the treatment of autoimmune diseases. Initially the oral formulation of arsenic trioxide will target the treatment of patients with chronic graft-versus-host disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MaaT013

            Therapeutic Area: Immunology Product Name: MaaT013

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Bpifrance

            Deal Size: $29.5 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing December 01, 2020

            Details:

            The final closing of the Series B financing will support the advancement of an innovative fermentation production platform to develop and manufacture both “standard” high-richness, high-diversity fermented product MaaT013, and a pipeline of indication-specific candidates.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MaaT013

            Therapeutic Area: Immunology Product Name: MaaT013

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 28, 2020

            Details:

            Data from the Company’s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will be highlighted in an e-poster presentation.